David Westenberg
Stock Analyst at Piper Sandler
(3.71)
# 686
Out of 4,870 analysts
169
Total ratings
47.57%
Success rate
7.66%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $55 → $70 | $65.65 | +6.63% | 4 | May 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $1.25 | $1.19 | +5.04% | 8 | May 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $205 → $210 | $170.37 | +23.26% | 15 | May 15, 2025 | |
| ILMN Illumina | Maintains: Overweight | $190 → $185 | $90.61 | +104.17% | 16 | May 15, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $205 → $210 | $157.34 | +33.47% | 14 | May 12, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $260 → $280 | $261.04 | +7.26% | 4 | May 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $12 | $7.01 | +71.18% | 9 | May 6, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $60 | $48.55 | +23.58% | 9 | May 6, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $16 → $23 | $19.31 | +19.11% | 8 | May 6, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $11 → $13 | $10.56 | +23.11% | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $179.72 | +11.28% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $4.77 | +4.82% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2.4 → $1.65 | $1.29 | +27.91% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $12 | $13.35 | -10.11% | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.12 | +156.41% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $52.54 | +33.23% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $524.65 | -2.79% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $10.79 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $27.65 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $56.45 | - | 1 | Nov 21, 2017 |
Tempus AI
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $65.65
Upside: +6.63%
Pacific Biosciences of California
May 15, 2025
Maintains: Neutral
Price Target: $2 → $1.25
Current: $1.19
Upside: +5.04%
Natera
May 15, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $170.37
Upside: +23.26%
Illumina
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $90.61
Upside: +104.17%
Zoetis
May 12, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $157.34
Upside: +33.47%
Labcorp Holdings
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $261.04
Upside: +7.26%
NeoGenomics
May 6, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $7.01
Upside: +71.18%
Guardant Health
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $48.55
Upside: +23.58%
Fulgent Genetics
May 6, 2025
Maintains: Neutral
Price Target: $16 → $23
Current: $19.31
Upside: +19.11%
Adaptive Biotechnologies
May 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $10.56
Upside: +23.11%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $179.72
Upside: +11.28%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $4.77
Upside: +4.82%
Apr 14, 2025
Maintains: Neutral
Price Target: $2.4 → $1.65
Current: $1.29
Upside: +27.91%
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $13.35
Upside: -10.11%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.12
Upside: +156.41%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $52.54
Upside: +33.23%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $524.65
Upside: -2.79%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $10.79
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $27.65
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $56.45
Upside: -